These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 33067401)

  • 1. Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study.
    Trucco F; Ridout D; Scoto M; Coratti G; Main ML; Muni Lofra R; Mayhew AG; Montes J; Pane M; Sansone V; Albamonte E; D'Amico A; Bertini E; Messina S; Bruno C; Parasuraman D; Childs AM; Gowda V; Willis T; Ong M; Marini-Bettolo C; De Vivo DC; Darras BT; Day J; Kichula EA; Mayer OH; Navas Nazario AA; Finkel RS; Mercuri E; Muntoni F;
    Neurology; 2021 Jan; 96(4):e587-e599. PubMed ID: 33067401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3.
    Trucco F; Ridout D; Weststrate H; Scoto M; Rohwer A; Coratti G; Main ML; Mayhew AG; Montes J; De Sanctis R; Pane M; Pera MC; Sansone VA; Albamonte E; D'Amico A; Bruno C; Messina SS; Childs AM; Willis T; Ong MT; Servais L; Majumdar A; Hughes I; Marini-Bettolo C; Parasuraman D; Gowda VL; Baranello G; Bertini ES; De Vivo DC; Darras BT; Day JW; Mayer O; Zolkipli-Cunningham Z; Finkel RS; Mercuri E; Muntoni F;
    Neurol Clin Pract; 2024 Jun; 14(3):e200298. PubMed ID: 38932995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3.
    Wolfe A; Stimpson G; Ramsey D; Coratti G; Dunaway Young S; Mayhew A; Pane M; Rohwer A; Muni Lofra R; Duong T; O'Reilly E; Milev E; Civitello M; Sansone VA; D'Amico A; Bertini E; Messina S; Bruno C; Albamonte E; Mazzone E; Main M; Montes J; Glanzman AM; Zolkipli-Cunningham Z; Pasternak A; Marini-Bettolo C; Day JW; Darras BT; De Vivo DC; Baranello G; Scoto M; Finkel RS; Mercuri E; Muntoni F;
    J Neuromuscul Dis; 2024; 11(3):665-677. PubMed ID: 38427497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal changes in respiratory and upper limb function in a pediatric type III spinal muscular atrophy cohort after loss of ambulation.
    Wolfe A; Scoto M; Milev E; Muni Lofra R; Abbott L; Wake R; Rohwer A; Main M; Baranello G; Mayhew A; Marini-Bettolo C; Muntoni F
    Muscle Nerve; 2021 Nov; 64(5):545-551. PubMed ID: 34432301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nusinersen in adults with type 3 spinal muscular atrophy: long-term outcomes on motor and respiratory function.
    Serrão C; Domingues S; de Campos CF; Moreira S; Conceição I; de Carvalho M; Oliveira Santos M
    Neurol Sci; 2024 Jun; 45(6):2887-2891. PubMed ID: 38589769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary function and scoliosis in children with spinal muscular atrophy types II and III.
    Chng SY; Wong YQ; Hui JH; Wong HK; Ong HT; Goh DY
    J Paediatr Child Health; 2003 Dec; 39(9):673-6. PubMed ID: 14629498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy.
    Bjelica B; Wohnrade C; Osmanovic A; Schreiber-Katz O; Petri S
    J Neurol; 2023 Jul; 270(7):3616-3622. PubMed ID: 37062018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year.
    Kaufmann P; McDermott MP; Darras BT; Finkel R; Kang P; Oskoui M; Constantinescu A; Sproule DM; Foley AR; Yang M; Tawil R; Chung W; Martens B; Montes J; O'Hagen J; Dunaway S; Flickinger JM; Quigley J; Riley S; Glanzman AM; Benton M; Ryan PA; Irvine C; Annis CL; Butler H; Caracciolo J; Montgomery M; Marra J; Koo B; De Vivo DC; ;
    Arch Neurol; 2011 Jun; 68(6):779-86. PubMed ID: 21320981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4.
    De Wel B; Goosens V; Sobota A; Van Camp E; Geukens E; Van Kerschaver G; Jagut M; Claes K; Claeys KG
    J Neurol; 2021 Mar; 268(3):923-935. PubMed ID: 32935160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2.
    Iwayama H; Kawahara K; Takagi M; Numoto S; Azuma Y; Kurahashi H; Yasue Y; Kawajiri H; Yanase A; Ito T; Kimura S; Kumagai T; Okumura A
    Brain Dev; 2023 Feb; 45(2):110-116. PubMed ID: 36335004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of scoliosis surgery on pulmonary function in spinal muscular atrophy type II patients.
    Chou SH; Lin GT; Shen PC; Lue YJ; Lu CC; Tien YC; Lu YM
    Eur Spine J; 2017 Jun; 26(6):1721-1731. PubMed ID: 27807779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hip Displacement in Spinal Muscular Atrophy: The Influences of Genetic Severity, Functional Level, and Disease-modifying Treatments.
    Ulusaloglu AC; Asma A; Shrader MW; Scavina MT; Mackenzie WG; Erb A; Howard JJ
    J Pediatr Orthop; 2024 Mar; 44(3):e226-e231. PubMed ID: 38073182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Bertsche A; Vill K; Baumann M; Baumgartner M; Cordts I; Eisenkölbl A; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Horber V; Husain RA; Illsinger S; Jahnel J; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schwerin-Nagel A; Reihle C; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Trollmann R; Weiler M; Weiß C; Wiegand G; Wilichowski E; Ziegler A; Lochmüller H; Kirschner J;
    Orphanet J Rare Dis; 2022 Oct; 17(1):384. PubMed ID: 36274155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory capacity course in patients with infantile spinal muscular atrophy.
    Ioos C; Leclair-Richard D; Mrad S; Barois A; Estournet-Mathiaud B
    Chest; 2004 Sep; 126(3):831-7. PubMed ID: 15364763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3.
    Maggi L; Bello L; Bonanno S; Govoni A; Caponnetto C; Passamano L; Grandis M; Trojsi F; Cerri F; Ferraro M; Bozzoni V; Caumo L; Piras R; Tanel R; Saccani E; Meneri M; Vacchiano V; Ricci G; Soraru' G; D'Errico E; Tramacere I; Bortolani S; Pavesi G; Zanin R; Silvestrini M; Politano L; Schenone A; Previtali SC; Berardinelli A; Turri M; Verriello L; Coccia M; Mantegazza R; Liguori R; Filosto M; Marrosu G; Siciliano G; Simone IL; Mongini T; Comi G; Pegoraro E
    J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1166-1174. PubMed ID: 32917822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of Pulmonary Function Measured by Patient-reported Outcomes in Patients With Spinal Muscular Atrophy After Growth-friendly Instrumentation.
    Matsumoto H; Mueller J; Konigsberg M; Ball J; St Hilaire T; Pawelek J; Roye DP; Cahill P; Sturm P; Smith J; Thompson G; Sponseller P; Skaggs D; Vitale MG
    J Pediatr Orthop; 2021 Jan; 41(1):1-5. PubMed ID: 32804864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiographic and Respiratory Effects of Growing Rods in Children With Spinal Muscular Atrophy.
    Lenhart RL; Youlo S; Schroth MK; Noonan KJ; McCarthy J; Mann D; Hetzel S; Sund SA; Halanski MA
    J Pediatr Orthop; 2017 Dec; 37(8):e500-e504. PubMed ID: 27636914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.